



PTO/SB/08b (11-08)

Approved for use through 12/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. FAIRNESS AND TRANSPARENCY OFFICE, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				<i>Complete If Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/655,861
				Filing Date	September 5, 2003
				First Named Inventor	YI Wang
				Art Unit	1644
				Examiner Name	F. P. Vandervegt
(Use as many sheets as necessary)				Attorney Docket Number	ALXN-P01-102
Sheet	1	of	1		

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

---

**FOREIGN PATENT DOCUMENTS**

---

Examiner Signature	Date Considered	
-----------------------	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and note considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.16). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kinds of documents indicated by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/PM	CO1	Matis and Rollins, Complement-specific antibodies: Designing novel anti-inflammatories, Nature Medicine, Vol. 1 No. 8, 1995	

Examiner Signature /F Pierre VanderVegt/ Date Considered 03/30/2009

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Air Mail, No. 111665446 US, on the date shown below in an envelope addressed to:  
MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: December 8, 2008 Signature: Pamela A. Hamson (Pamela A. Hamson)